Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTB | P49356 | 4/20 | 0.86 |
| ▸ | FNTA | P49354 | 3/20 | 0.86 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.86 |
| ▸ | EGFR | P00533 | 1/20 | 0.85 |
| ▸ | FYN | P06241 | 1/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.85 |
| ▸ | DRD2 | P14416 | 1/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.85 |
| ▸ | TACR2 | P21452 | 1/20 | 0.85 |
| ▸ | MC5R | P33032 | 1/20 | 0.85 |
| ▸ | DRD3 | P35462 | 1/20 | 0.85 |
| ▸ | MC3R | P41968 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.85 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723220 | 1.00 | FNTB (0.86) | FNTBFNTAPGGT1BEGFRFYN | |
| SCHEMBL17534944 | 1.00 | FNTB (0.86) | FNTBFNTAPGGT1BEGFRFYN | |
| SCHEMBL2723214 | 1.00 | FNTB (0.86) | FNTBFNTAPGGT1BEGFRFYN | |
| SCHEMBL14640162 | 1.00 | FNTB (0.86) | FNTBFNTAPGGT1BEGFRFYN | |
| SCHEMBL16111867 | 1.00 | FNTB (0.86) | FNTBFNTAPGGT1BEGFRFYN | |
| SCHEMBL5310547 | 1.00 | FNTB (0.86) | FNTBFNTAPGGT1BEGFRFYN | |
| SCHEMBL1683561 | 1.00 | FNTB (0.86) | FNTBFNTAPGGT1BEGFRFYN | |
| SCHEMBL5310552 | 1.00 | FNTB (0.86) | FNTBFNTAPGGT1BEGFRFYN | |
| SCHEMBL17534946 | 1.00 | FNTB (0.86) | FNTBFNTAPGGT1BEGFRFYN | |
| SCHEMBL16111866 | 1.00 | FNTB (0.86) | FNTBFNTAPGGT1BEGFRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225671-A1 | Methods of Treating Seizure Disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2012054724-A1 | METHODS OF TREATING SEIZURE DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225671-A1 | Methods of Treating Seizure Disorders | NRAS, FAH, HMGCR | FNTB 37/4885FNTA 12/4885PGGT1B 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.